Vanguard Group
FNCH

Vanguard Group’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Vanguard Group’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,252
Closed -$94.3K – 4518
2024
Q1 		$94.3K Sell
36,252
-2,512
-6% -$7K ﹤0.01% 4251
2023
Q4 		$140K Buy
38,764
+2,825
+8% +$11.1K ﹤0.01% 4264
2023
Q3 		$186K Buy
35,939
+3,263
+10% +$23.5K ﹤0.01% 4260
2023
Q2 		$279K Sell
32,676
-1,157
-3% -$11.9K ﹤0.01% 4255
2023
Q1 		$399K Hold
33,833
– – ﹤0.01% 4183
2022
Q4 		$487K Buy
33,833
+162
+0.5% +$5.42K ﹤0.01% 4107
2022
Q3 		$1.69M Hold
33,671
– – ﹤0.01% 3812
2022
Q2 		$2.87M Buy
33,671
+7,194
+27% +$615K ﹤0.01% 3648
2022
Q1 		$3.99M Sell
26,477
-88
-0.3% -$20.3K ﹤0.01% 3634
2021
Q4 		$7.95M Buy
26,565
+20,667
+350% +$7.93M ﹤0.01% 3350
2021
Q3 		$2.3M Buy
5,898
+71
+1% +$30.3K ﹤0.01% 4018
2021
Q2 		$2.46M Buy
5,827
+4,660
+399% +$2.02M ﹤0.01% 3911
2021
Q1 		$565K Buy
+1,167
New +$594K ﹤0.01% 4113

Other funds holding FNCH

LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Vanguard Group's FNCH Position: Q2 2024 in Review

Vanguard Group sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 36,252 shares — an estimated $94.3K sold.

Vanguard Group first reported a position in FNCH in Q1 2021 and held it in 13 quarters. The position peaked at $7.95M in Q4 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

  • Vanguard Group reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 36,252 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $94.3K.
  • Vanguard Group first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Vanguard Group's Finch Therapeutics Group, Inc. Common Stock position peaked at $7.95M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.